Research

Skeletal muscle oxygen saturation does not estimate mixed venous oxygen saturation in patients with severe left heart failure and additional severe sepsis or septic shock

Matej Podbregar and Hugon Možina

Clinical Department for Intensive Care Medicine, University Clinical Centre, Zaloska 7, 1000 Ljubljana, Slovenia

Corresponding author: Matej Podbregar, Matej.Podbregar@guest.arnes.si

Abstract

Introduction Low cardiac output states such as left heart failure are characterized by preserved oxygen extraction ratio, which is in contrast to severe sepsis. Near infrared spectroscopy (NIRS) allows noninvasive estimation of skeletal muscle tissue oxygenation (StO_2). The aim of the study was to determine the relationship between StO_2 and mixed venous oxygen saturation (SvO_2) in patients with severe left heart failure with or without additional severe sepsis or septic shock.

Methods Sixty-five patients with severe left heart failure due to primary heart disease were divided into two groups: groups A (n = 24) and B (n = 41) included patients without and with additional severe sepsis/septic shock, respectively. Thenar muscle StO_2 was measured using NIRS in the patients and in 15 healthy volunteers.

Results StO_2 was lower in group A than in group B and in healthy volunteers (58 ± 13%, 90 ± 7% and 84 ± 4%, respectively; P < 0.001). StO_2 was higher in group B than in

healthy volunteers (P = 0.02). In group A StO_2 correlated with SvO_2 (r = 0.689, P = 0.002), although StO_2 overestimated SvO_2 (bias -2.3%, precision 4.6%). In group A changes in StO_2 correlated with changes in SvO_2 (r = 0.836, P < 0.001; ΔSvO_2 = 0.84 × ΔStO_2 - 0.67). In group B important differences between these variables were observed. Plasma lactate concentrations correlated negatively with StO_2 values only in group A (r = -0.522, P = 0.009; lactate = -0.104 × StO_2 + 10.25).

Conclusion Skeletal muscle StO_2 does not estimate SvO_2 in patients with severe left heart failure and additional severe sepsis or septic shock. However, in patients with severe left heart failure without additional severe sepsis or septic shock, StO_2 values could be used to provide rapid, noninvasive estimation of SvO_2; furthermore, the trend in StO_2 may be considered a surrogate for the trend in SvO_2.

Trial Registration: NCT00384644

Introduction

Maintenance of adequate oxygen delivery (DO_2) is essential to preservation of organ function, because sustained low DO_2 leads to organ failure and death [1]. Low cardiac output states (cardiogenic, hypovolaemic and obstructive types of shock) and anaemic and hypoxic hypoxaemia are characterized by decreased DO_2 but preserved oxygen extraction ratio. In distributive shock, the oxygen extraction capability is altered so that the critical oxygen extraction ratio is typically decreased [2]. Mixed venous oxygen saturation (SvO_2), measured from the pulmonary artery, is used in the calculation of oxygen consumption and has been advocated as an indirect index of tis-

sue oxygenation and a prognostic predictor in critically ill patients [3-6]. However, catheterization of the pulmonary artery is costly, has inherent risks and its usefulness remains subject to debate [7-9].

Near infrared spectroscopy (NIRS) is a technique that permits continuous, noninvasive, bedside monitoring of tissue oxygen saturation (StO_2) [9,10]. We previously showed that thenar muscle StO_2 during stagnant ischaemia decreases at a slower rate in patients with septic shock than in patients with severe sepsis or localized infection and in healthy volunteers [11]. Patients included in the study had normal heart function and

---

DO_2 = oxygen distribution; ICU = intensive care unit; NIRS = near infrared spectroscopy; $ScvO_2$ = central venous oxygen saturation; SOFA = Sepsis-related Organ Failure Assessment; StO_2 = tissue oxygenation; SvO_2 = mixed venous oxygen saturation.

were haemodynamically stable; they also had normal or higher StO_2. However, in every day clinical practice, we noticed extreme low levels of StO_2, especially in patients with cardiogenic shock.

Our aim in the present study was to evaluate skeletal muscle oxygenation in severe left heart failure with or without additional severe sepsis/septic shock and to compare with with SvO_2. The hypothesis was that StO_2 may estimate SvO_2 in patients severe left heart failure and preserved oxygen extraction capability (without severe sepsis/septic shock), because blood flowing through upper limb muscles could importantly contribute to flow through the superior vena cava. On the other hand, in patients with decreased oxygen extraction capability (with severe sepsis/septic shock), we expected disagreement between StO_2 and SvO_2, because in these patients greater oxygen extraction can probably take place in organs other than skeletal muscles.

Materials and methods
Patients
The study protocol was approved by the National Ethics Committee of Slovenia; informed consent was obtained from all patients or their relatives. The study was performed during the period between October 2004 and June 2006. Following initial heamodynamic resuscitation, heart examination was performed in all patients admitted to our intensive care unit (ICU) using transthoracic ultrasound (Hewlett-Packard HD 5000; Hewlett-Packard, Andover, MA, USA). In patients with primary heart disease, low cardiac output and no signs of hypovolaemia, right heart catheterization with a pulmonary artery floating catheter (Swan-Ganz CCOmboV CCO/SvO$_2$/CEDV; Edwards Lifesciences, Irvine, CA, USA) was performed at the descretion of the treating physician. The site of insertion was confirmed by the transducer waveform, the length of catheter insertion and chest radiography. Systemic arterial pressure was measured invasively using radial or femoral arterial catheterization.

Patients with severe left heart failure due to primary heart disease (left ventricular systolic ejection fraction < 40%, pulmonary artery occlusion pressure > 18 mmHg) were included. The patients were prospectively divided into two groups; group A included patients without severe sepsis or septic shock and group B included patients with additional severe sepsis or septic shock. Severe sepsis and septic shock were defined according to the 1992 American College of Chest Physicians and the Society of Critical Care Medicine consensus conference definitions [12].

All patients received standard treatment for localized infection, severe sepsis and septic or cardiogenic shock, including source control, fluid infusion, catecholamine infusion, replacement and/or support therapy for organ failure, intensive control of blood glucose and corticosteroid substitution therapy, in accordance to current Surviving Sepsis Campaign Guidelines [13]. Mechanically ventilated patients were sedated with midazolam and/or propofol infusion, and no paralytic agents were used.

Fifteen healthy volunteers served as a control group.

Measurements
Skeletal muscle oxygenation
Thenar muscle StO_2 was measured noninvasively by NIRS (InSpectra™; Hutchinson Technology Inc., Hutchinson, MN, USA). Maximal thenar muscle StO_2 was determined by moving the probe over the thenar prominence. StO_2 was continuously monitored and stored in a computer using InSpectra™ software. The average StO_2 over 15 seconds was used. Measurements were performed immediately after right heart catheterization using pulmonary artery floating catheter insertion (during the first 24 hours after admission). The time between admission and measurement is reported. Measurements in spontaneously breathing patients and healthy volunteers were taken after 15 minutes of bed rest, avoiding any muscular contractions.

Severity of disease
Sepsis-related Organ Failure Assessment (SOFA) score was calculated at the time of each measurement to assess the level of organ dysfunction [14]. Dobutamine, norepinephrine requirement represented the dose of drug during the StO_2 measurement. Also reported is use of intra-aortic balloon pump during ICU stay.

Plasma lactate concentration was measured using enzymatic colorimetric method (Roche Diagnostics GmbH, Mannheim, Germany) at the time of each StO_2 measurement.

Laboratory analysis
Blood was drawn from the pulmonary artery at the time of each StO_2 measurement in order to determine the SvO_2 (%). In view of the known problems that may arise during sampling from the pulmonary artery, including the possibility arterial blood may be contaminated with pulmonary capillary blood, all samples from this site were drawn over 30 seconds, using a low-negative pressure technique, and never with the balloon inflated. A standard volume of 1 ml blood was obtained from each side after withdrawal of dead-space blood and flushing fluid. All measurements were made using a cooximeter (RapidLab 1265; Bayer HealthCare AG, Leverkusen, Germany).

Study of agreement between trends of StO_2 and SvO_2
In ten patients from group A and eight patients from group B, StO_2 and SvO_2 (Vigilance CEDV; Edwards Lifesciences) were continuously monitored and recorded every 15 minutes for one hour to study agreement between trends in measured variables.

Table 1

Description of patients

Parameter	All ($n = 65$)	Group A ($n = 24$)	Group B ($n = 41$)	P value
Age (years)	69 ± 15	68 ± 14	70 ± 16	0.2
Female (n)	36	12	24	0.9
Ischaemic heart disease (n)	51	19	32	0.9
Aoritc stenosis (n)	12	4	8	0.9
Dilated cardiomyopathy (n)	2	1	1	0.7
LVEF (%)	30 ± 10	28 ± 12	32 ± 8	0.2
LVEDD (cm)	5.8 ± 0.9	5.9 ± 1.0	5.8 ± 0.8	0.3
Severe mitral regurgitation (n)	21	8	13	0.9
Time between admission and measurement (hours)	6.4 ± 4.4	6.0 ± 4.8	6.6 ± 4.5	0.6
SOFA score	11.8 ± 2.5	11.6 ± 2.5	11.9 ± 2.7	0.8
ICU stay (days)	8 ± 3	7 ± 4	10 ± 3	0.9
ICU survival (%	47	45	50	0.8

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. ICU, intensive care unit; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; SOFA, Sequential Organ Failure Assessment.

Data analysis

Data are expressed as mean ± standard deviation. Student's *t*-test, Kolmogorov-Smirnov Z test and χ^2 test (Yates correction) were applied to analyze data (SPSS 10.0 for Windows™; SPSS Inc., Cary, NC, USA). One-way analysis of variance with Dunnett T3 test for post-hoc multiple comparisons were used to compare muscle tissue StO_2 between healthy volunteers and both groups. Spearman correlation test was applied to determine correlation. To compare muscle tissue StO_2 and SvO_2, bias, systemic disagreement between measurements (mean difference between two measurements) and precision (the random error in measuring [standard deviation of bias]) were calculated [14]. The 95% limits of agreement were arbitrarily set, in accordance with Bland and Altman [15], as the bias ± 2 standard deviations. $P < 0.05$ (two-tailed) was considered statistically significant.

Results

Included in the study were 65 patients (36 women and 29 men; mean age 68 ± 14 years) with primary heart disease (ischaemic heart disease in 51 patients, aortic valve stenosis in 12 and dilated cardiomyopathy in two). In 24 patients (group A) severe left heart failure or cardiogenic shock but no additional severe sepsis/septic shock was the reason for ICU admission. In 25 patients severe sepsis and in 16 patients septic shock was diagnosed (group B; $n = 41$). Suspected pneumonia was main source of infection (35 patients [85%]), followed by urinary tract infection (six patients [15%]). In 80% of patients pathogenic bacteria were isolated.

There was no difference in age, sex, aetiology of primary heart disease, echocardiography data, time between admission and measurements, SOFA score, duration of ICU stay and survival between groups (Table 1). Fifteen healthy volunteers (eight women and seven men; age 40 ± 12 years) were included in the control group.

Patients in group A received higher doses of dobutamine (Table 2). There was no difference in lactate value, haemoglobin level and leucocyte count; however C-reactive protein and procalcitonin values were higher in group B patients (Table 3). Patients in group A had lower cardiac index, DO_2 and SvO_2, and higher oxygen extraction ratio compared with patients in group B (Table 4).

In group A StO2 was lower than in group B patients and in healthy volunteers (58 ± 13%, 90 ± 7% and 84 ± 4%, respectively; P < 0.001). StO2 was higher in group B patients than in healthy volunteers (P = 0.02). In group A StO2 correlated with SvO2 (r = 0.689, P = 0.002), but no correlation was observed between StO2 and SvO2 in group B (r = -0.091, P = 0.60; Figure 1). In group A StO2 slightly overestimated SvO2 (bias -2.3%, precision 4.6%; Figure 2). In group B StO2 overestimated SvO2, but important disagreement between these variables was observed. In three of our patients with septic shock a skeletal muscle StO2 of 75% or lower (lower bound of the 95% confidence interval for mean StO2 in control individuals) was detected.

Table 2

Treatment of patients

Treatment	All ($n = 65$)	Group A ($n = 24$)	Group B ($n = 41$)	*P* value
Norepinephrine (mg/min)	0.048 ± 0.049	0.039 ± 0.042	0.051 ± 0.052	0.39
Dobutamine (mg/min)	0.40 ± 0.31	**0.53 ± 0.33**	**0.33 ± 0.28**	**0.05**
IABP (*n*)	15	**15**	**0**	**0.01**
Mechanical ventilation (*n*)	60	22	38	0.9
FiO$_2$ (%)	72 ± 22	**82 ± 19**	**68 ± 23**	**0.04**

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. FiO$_2$, fractional inspired oxygen; IABP, intra-aortic balloon pump.

In 10 patients from group A 42 pairs of SvO2-StO2 changes were recorded. Changes in StO2 correlated with changes in SvO2 ($r = 0.836$, R2 = 0.776, P < 0.001); the equation for the regression line was as follows (Figure 3): ΔSvO2 (%) = 0.84 × ΔStO2 (%) - 0.67. In eight patients from group B 38 pairs of SvO2-StO2 changes were recorded. In group B changes in StO2 did not correlate with changes in SvO2 ($r = 0.296$, R2 = 0.098, P = 0.071).

Plasma lactate concentrations correlated negatively with StO$_2$ values in group A ($n = 24$; $r = -0.522$, $P = 0.009$, $R^2 = 0.263$; lactate [mmol/l] = -0.104 × StO$_2$ [%] + 10.25); there was no correlation between lactate and StO$_2$ in group B.

Discussion

The main result of the study is that skeletal muscle StO$_2$ does not estimate SvO$_2$ in patients with severe left heart failure and additional severe sepsis or septic shock. However, in patients with severe left heart failure without additional severe sepsis or septic shock, the StO$_2$ value could be used as a fast and non-invasive estimate of SvO$_2$; also, the trend in StO$_2$ may be considered a surrogate for the trend in SvO$_2$.

Skeletal muscle StO$_2$ in patients with severe heart failure and additional severe sepsis or septic shock

We previously detected high StO$_2$ and slow deceleration in StO$_2$ during stagnant ischaemia in septic patients [11]. Our

Table 3

Laboratory data

Parameter	All ($n = 65$)	Group A ($n = 24$)	Group B ($n = 41$)	*P* value
Temperature (°C)	37.9 ± 0.9	38.0 ± 0.9	37.9 ± 0.9	0.9
Lactate (mmol/l)	3.5 ± 2.3	4.1 ± 2.5	3.1 ± 2.1	0.1
CRP (mg/l)	110 ± 84	**78 ± 72**	**128 ± 86**	**0.02**
PCT (mg/l)	5.0 ± 6.0	**2.5 ± 2.7**	**6.5 ± 6.8**	**0.02**
Leucocyte (× 10^6/l)	14.1 ± 7.2	14.5 ± 9.0	13.9 ± 5.2	0.6
Haemoglobin (mg/l)	112 ± 14	109 ± 11	114 ± 15	0.1
Creatinine (μmol/l)	199 ± 165	156 ± 148	227 ± 186	0.1
Arterial blood gas analysis				
pH	7.37 ± 0.03	7.38 ± 0.07	7.36 ± 0.1	0.5
PCO$_2$ (kPa)	4.8 ± 1.0	4.7 ± 1.1	4.9 ± 1.0	0.4
PO$_2$ (kPa)	16.6 ± 8.0	17.8 ± 10.8	15.9 ± 6.2	0.4
HCO$_3$ (mmol/l)	19.8 ± 5.7	**17.1 ± 2.6**	**21.0 ± 6.9**	**0.01**
BE (mEq/l)	-4.8 ± 5.7	**-7.4 ± 3.5**	**-3.6 ± 6.4**	**0.03**
SatHbO$_2$ (%)	97 ± 2	97 ± 1	97 ± 3	0.3

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. BE, base excess; CRP, C-reactive protein; PCO$_2$, partial carbon dioxide tension; PCO$_2$, partial oxygen tension; PCT, procalcitonin; SatHbO$_2$, haemoglobin oxygen saturation.

Table 4

Systemic haemodynamics and systemic oxygen transport data

Parameter	All ($n = 65$)	Group A ($n = 24$)	Group B ($n = 41$)	P value
Heart rate (beats/min)	111 ± 21	111 ± 24	111 ± 19	0.9
SAP (mmHg)	120 ± 22	122 ± 25	119 ± 22	0.8
DAP (mmHg)	73 ± 21	71 ± 22	74 ± 22	0.7
PAP_s (mmHg)	56 ± 14	57 ± 13	56 ± 12	0.2
PAP_d (mmHg)	28 ± 8	**31 ± 8**	**27 ± 8**	**0.01**
CVP (mmHg)	15 ± 4	17 ± 3	14 ± 5	0.051
PAOP (mmHg)	23 ± 6	24 ± 5	22 ± 7	0.9
CI (l/min per m²)	2.4 ± 0.7	**2.1 ± 0.6**	**2.6 ± 0.7**	**0.01**
SvO_2 (%)	63 ± 12	**56 ± 11**	**68 ± 10**	**0.01**
DO_2 (ml/min per m²)	366 ± 134	**301 ± 90**	**404 ± 142**	**0.001**
VO_2 (ml/min per m²)	120 ± 42	125 ± 42	117 ± 41	0.3
O_2ER (%)	35 ± 12	**43 ± 12**	**31 ± 11**	**0.001**

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. CI, cardiac index; CVP, central venous pressure; DAP, systemic diastolic artieral pressure; DO_2, oxygen delivery; O_2ER, oxygen extraction ratio; PAOP, pulmonary artery occlusion pressure; PAP_d, pulmonary artery diastolic pressure; PAP_s, pulmonary artery systolic pressure; SAP, systemic systolic arterial pressure; $ScvO_2$, central venous oxygen saturation; SvO_2, mixed venous oxygen saturation; VO_2, oxygen consumption.

data were in concordance with a previous report from De Blasi and coworkers [16]. Studies in animals and patients with sepsis confirmed the presence of increased tissue oxygen tension [17]. However, tissue oxygen consumption slows down in sepsis, and this correlates with the severity of sepsis [18]. Reduced cellular use/extraction of oxygen may be the problem rather than tissue hypoxia *per se*, because an increase in tissue oxygen tension is normally observed [19]. The high StO_2 levels seen in our patients with additional severe sepsis or septic shock support this hypothesis. Mitochondrial dysfunction has been implicated by Ince and Sinaasappel [20]. This mitochondrial alteration was also shown to correlate with outcome in sepsis and septic shock [21].

The high StO_2/low SvO_2, seen in severe sepsis and septic shock, suggest blood flow redistribution. Thenar muscle StO_2 probably correlates with central venous oxygen saturation ($ScvO_2$), which is measured in a mixture of blood from head and both arms. In healthy resting individuals $ScvO_2$ is slightly lower than SvO_2 [22]. Blood in the inferior vena cava has high oxygen content because the kidneys do not utilize much oxygen but receive a high proportion of cardiac output [23]. As a result, inferior vena caval blood has higher oxygen content than blood from the upper body, and SvO_2 is greater than $ScvO_2$.

This relationship changes in the presence of cardiovascular instability. Scheinman and coworkers [24] performed the earliest comparison of $ScvO_2$ and SvO_2 in both haemodynamically stable and shocked patients. In stable patients $ScvO_2$ was similar to SvO_2. In patients with failing heart $ScvO_2$ was

slightly higher than SvO_2 and in shock patients the difference between SvO_2 and $ScvO_2$ was even more pronounced (47.5 ± 15.11% and 58.0 ± 13.05%, respectively; $P < 0.001$). Lee and coworkers [25] described similar findings. Other, more detailed studies in mixed groups of critically ill patients designed to test whether the $ScvO_2$ measurements could substitute for SvO_2 demonstrated problematic large confidence limits [26] and poor correlation between the two values [27].

Most authors attribute this pattern to changes in the distribution of cardiac output that occur in the presence of haemodynamic instability. In shock states, blood flow to the splanchnic and renal circulations falls, whereas flow to the heart and brain is maintained [28]. This results in a fall in the oxygen content of blood in the inferior vena cava. As a consequence, in shock states the normal relationship is reversed and $ScvO_2$ is greater than SvO_2 [23-25]. Consequently, when using $ScvO_2$ (or probably StO_2) as a treatment goal, the relative oxygen consumption of the superior vena cava system may remain stable at a time when oxidative metabolism of vital organs, such as the splanchnic region, may reach a level at which flow-limited oxygen consumption occurs, together with marked decrease in oxygen saturation. In this situation StO_2 provides a falsely favourable impression of adequate body perfusion, because of the inability to detect organ ischemia in the lower part of the body.

In the present study three patients with septic shock had skeletal muscle StO_2 of 75% or less (under the lower bound of the 95% confidence interval for the mean StO_2 in control individ-

Figure 1

Correlation between skeletal muscle StO_2 and SvO_2. Group A includes patients with severe left heart failure without severe sepsis/septic shock, and group B includes patients with primary heart disease and additional severe sepsis/septic shock. A statistically significant correlation was found in group A ($r = 0.689$, $P = 0.002$) but not in group B ($r = -0.091$, $P = 0.60$). StO_2, tissue oxygenation; SvO_2, mixed venous oxygen saturation.

Figure 2

Agreement between SvO_2 and thenar muscle StO_2 in the absence of severe sepsis/septic shock. Shown are Bland and Altman plots of agreement between SvO_2 and thenar muscle StO_2 in patients with left heart failure without severe sepsis/septic shock ($n = 24$), The unbroken line indicates the mean difference (bias), and broken lines indicate 95% limits of agreement (mean ± standard deviation). StO_2, tissue oxygenation; SvO_2, mixed venous oxygen saturation.

uals); they were all in septic shock (lactate value > 2.5 mmol/l) with low cardiac index (< 2.0 l/min per m²). These patients were probably in an early under-resuscitated phase of septic shock. Low numbers of septic patients with low StO_2 values

did not allow us to study the agreement between StO_2 and SvO_2 in such patients; however, there was a wide range in StO_2 values with SvO_2 below 65%. Additional research is necessary to study muscle skeletal StO_2 in under-resuscitated septic patients.

Skeletal muscle StO_2 in patients with severe heart failure without additional severe sepsis or septic shock

Our data are supported by previous work conducted by Boekstegers and coworkers [29], who measured the oxygen partial pressure distribution in biceps muscle. They found low peripheral oxygen availability in cardiogenic shock compared with sepsis. In cardiogenic shock skeletal muscle partial pressure of oxygen correlated with systemic DO_2 ($r = 0.59$, $P < 0.001$) and systemic vascular resistance ($r = 0.74$, $P < 0.001$). No correlation was found between systemic oxygen transport variables and skeletal muscle partial oxygen pressure in septic patients. These measurements were taken in the most common cardiovascular state in sepsis; this is in contrast to hypodynamic shock, which is only present in the very final stages of sepsis or in patients without adequate volume replacement [30]. In a subsequent study, those authors showed that even in the final state of hypodynamic septic shock, leading to death, the mean muscle partial oxygen pressure did not decrease to under 4.0 kPa before circulatory standstill took place [31].

In a human validation study [32] a significant correlation between NIRS-measured StO_2 and venous oxygen saturation ($r = 0.92$, $P < 0.05$) was observed; the venous effluent was obtained from a deep forearm vein that drained the exercising muscle. StO_2 was minimally affected by skin blood flow. Changes in limb perfusion affect StO_2; skeletal muscle StO_2 decreases during norepinephrine and increases during nitroprusside infusion.

In shock with preserved or even increased oxygen extraction, such as haemorrhagic shock, StO_2 (as measured by NIRS in skeletal muscle, stomach and liver) correlated with systemic DO_2 in a pig model [33]. Changes in skeletal muscle oxygen partial pressure were confirmed during haemorrhagic shock and resuscitation [34]. Continuous monitoring of skeletal muscle StO_2 is already used in trauma patients, in whom it identifies the severity of shock [35]. Basal skeletal muscle StO_2 can track systemic DO_2 during and after resuscitation of trauma patients [36].

StO_2 overestimated SvO_2 (bias -2.5%) in the present study. This may be due to the NIRS method, which does not discriminate between compartments. It provides a global assessment of oxygenation in all vascular compartments (arterial, venous and capillary) in sample volume of underlying tissue. This is major limitation of the present study. The noninvasive measurement of only venous oxygen saturation is complicated by the fact that isolation of the contribution of venous compartment

Figure 3

Concordance between changes in SvO_2 and changes in thenar muscle StO_2 in the absence of severe sepsis/septic shock. Shown are changes in SvO_2 and thenar muscle StO_2 in 10 patients with severe left heart failure without additional severe sepsis/septic shock (group A; $n = 40$, $r = 0.836$, $R^2 = 0.776$, $P < 0.001$; equation of the regression line: ΔSvO_2 [%] $= 0.84 \times \Delta StO_2$ [%] $- 0.67$). StO_2, tissue oxygenation; SvO_2, mixed venous oxygen saturation.

to the noninvasive optical signal is not straightforward. New methods like near-infrared spiroximetry, which measures venous oxygen saturation in tissue from the near-infrared spectrum of the amplitude of respiration-induced absorption oscillations, may lead to the design of a noninvasive optical instrument that can provide simultaneous and real-time measurements of local arterial, tissue and venous oxygen saturation [37].

In low flow states, in which controversies regarding monitoring persist [38], it appears logical to make use of both macro- and microcirculatory parameters to guide resuscitation efforts [39]. A large prospective study is currently being performed to evaluate the utility of additional StO_2 regional monitoring to guide tissue oxygenation, in addition to the early goal-directed therapy proposed by Rivers and coworkers [40].

Conclusion

In patients with severe left heart failure without additional severe sepsis or septic shock, SvO_2 provides a noninvasive estimate of and tracks with StO_2. It should be emphasized that in patients with severe heart failure and additional severe sepsis or septic shock, skeletal muscle StO_2 provides a falsely favourable impression of body perfusion.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

MP was responsible for conception and design of the study; for acquisition of data, and its analysis and interpretation; and for drafting the manuscript. HM was responsible for conception and design of the study; for acquisition of data, and its analysis and interpretation; and for drafting the manuscript.

References

1. Vincent JL, De Backer D: **Oxygen transport: the oxygen delivery controversy.** *Intensive Care Med* 2004, **30:**1990-1996.
2. Lim N, Dubois MJ, De Backer D, Vincent JL: **Do all nonsurvivors of cardiogenic shock die with low cardiac index?** *Chest* 2003, **124:**1885-1891.
3. Goldman RH, Klughaupt M, Metcalf T, Spivak AP, Harrison DC: **Measurement of central venous oxygen saturation in patients with myocardial infarction.** *Circulation* 1968, **38:**941-946.
4. Kasnitz P, Druger GL, Zorra F, Simmons DH: **Mixed venous oxygen tension and hyperlactemia. Survival in severe cardiopulmonary disease.** *JAMA* 1976, **236:**570-574.
5. Krafft P, Steltzer H, Hiesmayr M, Klimscha W, Hammerle AF: **Mixed venous oxygen saturation in critically ill septic shock patients. The role of defined events.** *Chest* 1993, **103:**900-906.
6. Edwards JD: **Oxygen transport in cardiogenic and septic shock.** *Crit Care Med* 1991, **19:**658-663.
7. Dalen JE, Bone RC: **Is it time to pull the pulmonary artery catheter?** *JAMA* 1996, **276:**916-918.
8. Reinhart K, Radermacher P, Sprung CL, Phelan D, Bakker J, Steltzer H: **PA catheterisation – quo vadis? Do we have to change the current practice with this monitoring device.** *Intensive Care Med* 1997, **23:**605-609.
9. Boushel R, Piantadosi CA: **Near-infrared spectroscopy for monitoring muscle oxygenation.** *Acta Physiol Scand* 2000, **168:**615-622.
10. Wahr JA, Tremper KK, Samra S, Delpy DT: **Near-infrared spectroscopy: theory and applications.** *J Cardiothorac Vasc Anesth* 1996, **10:**406-418.
11. Pareznik R, Voga G, Knezevic R, Podbregar M: **Changes of muscle tissue oxygenation during stagnant ishemia in septic patients.** *Intensive Care Med* 2006, **32:**87-92.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: **Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.** *Chest* 1992, **101:**1644-1655.
13. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, *et al.*: **Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.** *Intensive Care Med* 2004, **30:**536-555.

14. Vincent JL, Moreno R, Takala J, Willatts S, De Medonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: **The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure.** *Intensive Care Med* 1996, **22:**707-710.

15. Bland JM, Altman DG: **Statistical methods for assessing agreement between two methods of clinical measurements.** *Lancet* 1986, **21:**307-310.

16. De Blasi RA, Palmisani S, Alampi D, Mercieri M, Romao R, Collini S, Pinto G: **Microvascular dysfunction and skeletal muscle oxygenation assessed by phase-modulation near-infrared spectroscopy in patients with septic shock.** *Intensive Care Med* 2005, **31:**1661-1668.

17. Sair M, Etherington PJ, Winlove P, Ewans TW: **Tissue oxygenation and perfusion in patients with systemic sepsis.** *Crit Care Med* 2001, **29:**1343-1349.

18. Kreymann G, Grosser S, Buggisch P, Gottschall C, Matthaei S, Greten H: **Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock.** *Crit Care Med* 1993, **21:**1012-1019.

19. Rosser DM, Stidwill RP, Jacobson D, Singer M: **Oxygen tension in the bladder epithelium increased in both high and low output endotoxemic sepsis.** *J Appl Physiol* 1995, **79:**1878-1882.

20. Ince C, Sinaasappel M: **Microcirculatory oxygenation and shunting in sepsis and shock.** *Crit Care Med* 1999, **27:**1369-1377.

21. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: **Association between mitochondrial dysfunction and severity and outcome of septic shock.** *Lancet* 2002, **360:**219-223.

22. Barratt-Boyes BG, Wood EH: **The oxygen saturation of blood in the venae cavae, right-heart chambers, and pulmonary vessels of healthy subjects.** *J Lab Clin Med* 1957, **50:**93-106.

23. Cargill W, Hickam J: **The oxygen consumption of the normal and diseased human kidney.** *J Clin Invest* 1949, **28:**526.

24. Scheinman MM, Brown MA, Rapaport E: **Critical assessment of use of central venous oxygen saturation as a mirror of mixed venous oxygen in severely ill cardiac patients.** *Circulation* 1969, **40:**165-172.

25. Lee J, Wright F, Barber R, Stanley L: **Central venous oxygen saturation in shock: a study in man.** *Anesthesiology* 1972, **36:**472-478.

26. Edwards JD, Mayall RM: **Importance of the sampling site for measurement of mixed venous oxygen saturation in shock.** *Crit Care Med* 1998, **26:**1356-1360.

27. Martin C, Auffray JP, Badetti C, Perrin G, Papazian L, Gouin F: **Monitoring of central venous oxygen saturation versus mixed venous oxygen saturation in critically ill patients.** *Intensive Care Med* 1992, **18:**101-104.

28. Forsyth R, Hoffbrand B, Melmon K: **Re-distribution of cardiac output during hemorrhage in the unanesthetized monkey.** *Circ Res* 1970, **27:**311.

29. Boekstegers P, Weidenhoefer St, Pilz G, Werdan K: **Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: comparison to limited infection and cardiogenic shock.** *Infection* 1991, **19:**317-323.

30. Parker MM, Parrillo JE: **Septic shock: hemodynamics and pathogenesis.** *JAMA* 1983, **250:**3324-3327.

31. Boekstegers P, Weidenhoefer , Kapsner T, Werdan K: **Skeletal muscle partial pressure of oxygen in patients with sepsis.** *Crit Care Med* 1994, **22:**640-650.

32. Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR: **Validation of near-infrared spectroscopy in humans.** *J Appl Physiol* 1994, **77:**2740-2747.

33. Taylor JH, Beilman GJ, Conroy MJ, Mulier KE, Dean Myers Gruessner A, Hammer BE: **Tissue energetics as measured by nuclear magnetic resonance spectroscopy during hemorrhagic shock.** *Shock* 2004, **21:**58-64.

34. Clavijo-Alvarez JA, Sims CA, Pinsky MR, Puyana JC: **Monitoring skeletal muscle and subcutaneous tissue acid-base status and oxygenation during hemorrhagic shock and resuscitation.** *Shock* 2005, **24:**270-275.

35. Crookes BA, Cohn SM, Bloch S, Amortegui J, Manning R, Li P, Proctor MS, Hallal AH, Blackbourne LH, Benjamin R, *et al.*: **Can near-infrared spectroscopy identify the severity of shock in trauma patients?** *J Trauma* 2005, **58:**806-816.

36. McKinley BA, Marvin RG, Cocanour CS, Moore FA: **Tissue hemoglobin O$_2$ saturation during resuscitation of traumatic shock monitored using near infrared spectroscopy.** *J Trauma* 2000, **48:**637-642.

37. Franceschini MA, Boas DA, Zourabian A, Diamond SG, Nadgir S, Lin DW, Moore JB, Fantini S: **Near-infrared spiroxymetry: noninvasive measurements of venous saturation in piglets and human subjects.** *J Appl Physiol* 2002, **92:**372-384.

38. Sakr Y, Vincent JL, Reinhart K, Payen D, Wiedermann CJ, Zandstra DF, Sprung CL: **Use of the pulmonary artery catheter is not associated with worse outcome in the ICU.** *Chest* 2005, **128:**2722-2731.

39. Verdant C, De Backer D: **How monitoring of the microcirculation may help us at the bedside?** *Curr Opin Crit Care* 2005, **11:**240-244.

40. Rivers EP, McIntyre L, Morro DC, Rivers KK: **Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity.** *CMAJ* 2005, **173:**1054-1065.